LifeMD offers Ozempic at $499 per month via Novo Nordisk collaboration

LifeMD (LFMD) announced an additional offering through its collaboration with Novo Nordisk (NVO) that provides access to Ozempic, a GLP-1 RA for patients with type 2 diabetes, at $499 per month. Through LifeMD’s integration with NovoCare Pharmacy, eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, now have direct access to all FDA-approved dose strengths of Ozempic within LifeMD’s end-to-end virtual care platform. LifeMD’s telehealth platform is seamlessly integrated with NovoCare Pharmacy to provide easy, reliable access to Novo Nordisk’s FDA-approved GLP-1 medications, Ozempic and Wegovy, at the most competitive cash-pay price. Patients benefit from a comprehensive care journey that includes: Virtual consultations with LifeMD’s 50-state affiliated medical group, Ongoing clinical support from licensed providers, Access to nationwide diagnostic testing, Pharmacy coordination with fast, reliable shipping and real-time order tracking, and Simplified billing and payment options.